Nrx Pharmaceuticals Stock Today
| NRXPW Stock | USD 0.09 0.0007 0.75% |
PerformanceOK
| Odds Of DistressHigh
|
NRx Pharmaceuticals is selling for under 0.093099996 as of the 21st of March 2025; that is 0.75 percent decrease since the beginning of the trading day. The stock's lowest day price was 0.0931. NRx Pharmaceuticals has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 21st of December 2024 and ending today, the 21st of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 1st of December 2017 | Category Healthcare | Classification Health Care |
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was founded in 2015 and is based in Wilmington, Delaware. More on NRx Pharmaceuticals
Moving against NRx Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
NRx Stock Highlights
| CEO Secretary | Stephen Esq | |||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||
NRx Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand NRx Pharmaceuticals' financial leverage. It provides some insight into what part of NRx Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||
NRx Pharmaceuticals (NRXPW) is traded on NASDAQ Exchange in USA. It is located in 1201 Orange Street, Wilmington, DE, United States, 19801 and employs 14 people. NRx Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 714.61 M. NRx Pharmaceuticals classifies itself under Biotechnology sector and is part of Health Care industry.
NRx Pharmaceuticals has accumulated about 24.55 M in cash with (10.64 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.36, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check NRx Pharmaceuticals Probability Of Bankruptcy
NRx Pharmaceuticals Historical Income Statement
NRx Stock Against Markets
NRx Pharmaceuticals Corporate Management
| Suzanne Messere | Investor Relations | Profile | |
| Michael Abrams | Chief Officer | Profile | |
| Robert MIM | Chief Operations | Profile | |
| Michael Kunz | Gen Sec | Profile | |
| Molly Cogan | Sr Affairs | Profile |
Additional Tools for NRx Stock Analysis
When running NRx Pharmaceuticals' price analysis, check to measure NRx Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NRx Pharmaceuticals is operating at the current time. Most of NRx Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NRx Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NRx Pharmaceuticals' price. Additionally, you may evaluate how the addition of NRx Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.